IRF1 and neoplasm: The observed ARTD9-mediated down-regulation of tumor-suppressors IRF1 and TP53 may also represent a novel molecular mechanism inactivating the TP53/IRF1 pro- apoptotic pathway in high-risk DLBCL expressing wild-type TP53 [470].